Delivra Health Brands Announces Effective Date of Share Consolidation
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) has announced a share consolidation effective February 21, 2025. The consolidation will be implemented on a 1-for-10 basis, reducing the outstanding common shares from 312,617,854 to approximately 31,261,785.
The company's name will remain unchanged, with new CUSIP number 24703H201 and ISIN number CA24703H2019. The consolidation will adjust the exercise price and number of shares for existing stock options and warrants accordingly.
Registered shareholders holding physical certificates will receive a letter of transmittal to exchange their certificates, while beneficial shareholders holding shares through brokers won't need to complete this process.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) ha annunciato una consolidazione azionaria che entrerà in vigore il 21 febbraio 2025. La consolidazione sarà attuata su base 1 per 10, riducendo le azioni ordinarie in circolazione da 312.617.854 a circa 31.261.785.
Il nome della società rimarrà invariato, con un nuovo numero CUSIP 24703H201 e un numero ISIN CA24703H2019. La consolidazione modificherà il prezzo di esercizio e il numero di azioni per le opzioni azionarie e i warrant esistenti di conseguenza.
Gli azionisti registrati in possesso di certificati fisici riceveranno una lettera di trasmissione per scambiare i loro certificati, mentre gli azionisti beneficiari che detengono azioni tramite broker non dovranno completare questo processo.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) ha anunciado una consolidación de acciones que será efectiva el 21 de febrero de 2025. La consolidación se implementará en una base de 1 por 10, reduciendo las acciones ordinarias en circulación de 312,617,854 a aproximadamente 31,261,785.
El nombre de la compañía permanecerá sin cambios, con un nuevo número CUSIP 24703H201 y un número ISIN CA24703H2019. La consolidación ajustará el precio de ejercicio y el número de acciones para las opciones sobre acciones y warrants existentes en consecuencia.
Los accionistas registrados que posean certificados físicos recibirán una carta de transmisión para intercambiar sus certificados, mientras que los accionistas beneficiarios que posean acciones a través de corredores no necesitarán completar este proceso.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF)는 2025년 2월 21일부터 시행되는 주식 통합을 발표했습니다. 통합은 1대 10의 비율로 시행되어 발행된 보통주 수가 312,617,854주에서 약 31,261,785주로 줄어듭니다.
회사의 이름은 변경되지 않으며, 새로운 CUSIP 번호는 24703H201, ISIN 번호는 CA24703H2019입니다. 통합은 기존 주식 옵션과 워런트의 행사 가격 및 주식 수를 조정합니다.
물리적 증서를 보유한 등록 주주는 증서를 교환하기 위한 전송 서한을 받게 되며, 중개인을 통해 주식을 보유한 수익 주주는 이 과정을 완료할 필요가 없습니다.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) a annoncé une consolidation d'actions qui prendra effet le 21 février 2025. La consolidation sera mise en œuvre sur une base de 1 pour 10, réduisant le nombre d'actions ordinaires en circulation de 312 617 854 à environ 31 261 785.
Le nom de la société restera inchangé, avec un nouveau numéro CUSIP 24703H201 et un numéro ISIN CA24703H2019. La consolidation ajustera le prix d'exercice et le nombre d'actions pour les options d'achat d'actions et les bons de souscription existants en conséquence.
Les actionnaires enregistrés détenant des certificats physiques recevront une lettre de transmission pour échanger leurs certificats, tandis que les actionnaires bénéficiaires détenant des actions par l'intermédiaire de courtiers n'auront pas besoin de compléter ce processus.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) hat eine Aktienkonsolidierung angekündigt, die am 21. Februar 2025 in Kraft tritt. Die Konsolidierung wird im Verhältnis 1 zu 10 durchgeführt, wodurch die ausstehenden Stammaktien von 312.617.854 auf ungefähr 31.261.785 reduziert werden.
Der Name des Unternehmens bleibt unverändert, mit einer neuen CUSIP-Nummer 24703H201 und einer ISIN-Nummer CA24703H2019. Die Konsolidierung wird den Ausübungspreis und die Anzahl der Aktien für bestehende Aktienoptionen und Warrants entsprechend anpassen.
Registrierte Aktionäre, die physische Zertifikate halten, erhalten ein Übertragungsschreiben, um ihre Zertifikate auszutauschen, während begünstigte Aktionäre, die Aktien über Broker halten, diesen Prozess nicht abschließen müssen.
- Share consolidation could potentially improve stock marketability and attract institutional investors
- No change in shareholder equity value as consolidation is purely mechanical
- Significant reduction in outstanding shares may impact trading liquidity
- Administrative costs associated with the consolidation process
Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - Further to its press release dated January 27, 2025, Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company") announces that it will implement the consolidation of its issued and outstanding common shares (the "Common Shares") on the basis of one (1) new Common Share for every ten (10) existing Common Shares (the "Consolidation") effective as of February 21, 2025.
The Company's name will remain unchanged after the Consolidation. The new CUSIP number for the post-Consolidation Common Shares will be 24703H201 and the new ISIN number for the post-Consolidation Common Shares will be CA24703H2019.
As a result of the Consolidation, the 312,617,854 Common Shares issued and outstanding prior to the Consolidation, subject to rounding for fractional Common Shares, will be reduced to approximately 31,261,785 Common Shares. No fractional Shares will be issued in connection with the Consolidation.
The exercise price of the Company's existing incentive stock options under the Company's
Registered shareholders who hold physical certificates representing pre-Consolidation Common Shares will receive a letter of transmittal requesting that they forward such physical certificates to the Company's transfer agent, Computershare Trust Company Canada, in exchange for new physical certificates representing post-Consolidation Common Shares. Beneficial shareholders who hold Common Shares through a broker or other intermediary and do not have Common Shares registered in their own name will not be required to complete a letter of transmittal.
About Delivra Health Brands Inc.
Helping people take control of their health with alternative wellness solutions is what energizes the Delivra Health team! The Delivra Health portfolio features innovative brands like Dream Water® and LivRelief™, which deliver relief from common everyday issues like chronic pain, anxiety, and sleeplessness. Delivra Health products have allowed millions of customers to reclaim their mobility, energy, and in turn, quality of life. The websites of the Company's two subsidiaries are Dream Water® and LivReliefTM. For more information, please visit www.delivrahealthbrands.com.
Cautionary Note Regarding Forward-Looking Statements
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements include, among other things, statements with respect to the timing of the Consolidation.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the cannabis markets where the Company operates; changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; employee relations and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution, and sale of cannabis and cannabis-related products in the markets where the Company operates. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Additional information regarding this and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated March 2, 2021, and under the heading "Risks and Uncertainties" in the Company's management's discussion and analysis for the three months ended September 30, 2024 filed under the Company's profile on SEDAR+ at www.sedarplus.ca.
Investor Relations:
Jack Tasse
Chief Financial Officer
IR@delivrahealth.com
1-877-915-7934
Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/241275
FAQ
What is the consolidation ratio for Delivra Health Brands (DHBUF) shares announced in February 2025?
How many shares will Delivra Health (DHBUF) have outstanding after the February 2025 consolidation?
When will the Delivra Health (DHBUF) share consolidation take effect?
What happens to Delivra Health (DHBUF) stock options and warrants after the consolidation?
Do Delivra Health (DHBUF) shareholders need to take any action for the share consolidation?
